This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
by Zacks Equity Research
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
by Zacks Equity Research
ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
by Zacks Equity Research
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
by Zacks Equity Research
FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
by Zacks Equity Research
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts
by Zacks Equity Research
Strength in AVNS' Digestive Health segment drives its third-quarter performance
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
by Zacks Equity Research
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
by Zacks Equity Research
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
by Debanjana Dey
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
by Zacks Equity Research
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
by Zacks Equity Research
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Intuitive Surgical Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
by Zacks Equity Research
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
by Zacks Equity Research
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 26.67% and 1.46%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help AngioDynamics (ANGO) Maintain Its Recent Price Strength
by Zacks Equity Research
AngioDynamics (ANGO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
New Strong Buy Stocks for September 30th
by Zacks Equity Research
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
by Zacks Equity Research
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.